Eris Lifesciences Ltd
NSE:ERIS

Watchlist Manager
Eris Lifesciences Ltd Logo
Eris Lifesciences Ltd
NSE:ERIS
Watchlist
Price: 1 374.2 INR 0.53% Market Closed
Market Cap: 187B INR
Have any thoughts about
Eris Lifesciences Ltd?
Write Note

Eris Lifesciences Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Eris Lifesciences Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Eris Lifesciences Ltd
NSE:ERIS
Accounts Receivables
â‚ą4.2B
CAGR 3-Years
44%
CAGR 5-Years
38%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Accounts Receivables
â‚ą80.3B
CAGR 3-Years
17%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Accounts Receivables
â‚ą55.9B
CAGR 3-Years
17%
CAGR 5-Years
7%
CAGR 10-Years
13%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Accounts Receivables
â‚ą129.4B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
14%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Accounts Receivables
â‚ą17.8B
CAGR 3-Years
5%
CAGR 5-Years
3%
CAGR 10-Years
4%
M
Mankind Pharma Ltd
NSE:MANKIND
Accounts Receivables
â‚ą8.5B
CAGR 3-Years
37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Eris Lifesciences Ltd
Glance View

Market Cap
186.9B INR
Industry
Pharmaceuticals

Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2017-06-29. The Company’s manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals and nutrients (VMN). The firm's brands include Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Company’s wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited and Eris Healthcare Private Limited.

ERIS Intrinsic Value
1 082.77 INR
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Eris Lifesciences Ltd's Accounts Receivables?
Accounts Receivables
4.2B INR

Based on the financial report for Jun 30, 2024, Eris Lifesciences Ltd's Accounts Receivables amounts to 4.2B INR.

What is Eris Lifesciences Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
38%

Over the last year, the Accounts Receivables growth was 44%. The average annual Accounts Receivables growth rates for Eris Lifesciences Ltd have been 44% over the past three years , 38% over the past five years .

Back to Top